Evalyst (EOLS) Q2 2026: Portfolio Growth Bundle Drives 70% Cross-Sell, Expanding Share in Aesthetics
Evalyst’s Q2 marked a pivotal expansion of its injectable aesthetics platform, underpinned by robust double-digit growth and disciplined execution. The company’s portfolio strategy, highlighted by the successful debut of its growth bundle and international launches, is accelerating customer adoption and deepening wallet share. With new product verticals and geographic reach, Evalyst is positioning for sustained outperformance as the aesthetics market rebounds.
Summary
- Portfolio Strategy Accelerates: Evalyst’s cross-sell initiatives are driving deeper customer penetration and higher account spend.
- International and New Verticals Scale: Recent launches and licensing deals extend Evalyst’s reach and product mix.
- Execution Supports Upward Guidance: Operational leverage and market share gains bolster confidence in long-term targets.
Business Overview
Evalyst, an aesthetics-focused pharmaceutical company, generates revenue by marketing injectable neurotoxins and hyaluronic acid (HA) gels for cosmetic procedures. Its core business is built around Jeuveau, neurotoxin for wrinkle reduction, and Avelis, HA gel for volume and contouring. The company’s portfolio now spans three verticals: neurotoxins, HA gels, and skin quality injectables, with growing contributions from both U.S. and international markets.
Performance Analysis
Evalyst delivered strong double-digit revenue growth in Q2, fueled by broad-based gains across its toxin and HA gel franchises. Global toxin sales exceeded $75 million, supported by robust U.S. and international demand, while HA gel revenue reached $8.9 million, reflecting a sequential step-up in Avelis adoption. The launch of Esteem, HA gel collection, in Europe contributed incremental international growth, although still modest in scale.
Gross margin remained stable year-over-year when normalized for a one-time tariff refund, balancing a higher international mix with improved U.S. profitability. Operating expenses rose sequentially due to disciplined investments in customer education, marketing, and new market entry, but positive adjusted EBITDA was maintained for the third consecutive quarter, underscoring operational leverage. The company’s cash position and undrawn credit facility provide ample flexibility for ongoing expansion and innovation.
- Cross-Sell Penetration Surges: The portfolio growth bundle drove 70% Avelis adoption among participating accounts, compared to 25% across the total base.
- International Contribution Rises: Both Avelis and international business are on track to each exceed 10% of total revenue in 2026.
- Operating Discipline Evident: Evalyst continues to scale investments without sacrificing profitability, setting a foundation for future margin expansion.
Overall, Evalyst’s financial trajectory is outpacing original guidance, prompting a raise in full-year revenue and margin targets.
Executive Commentary
"The second quarter represents a meaningful inflection point for Evalyst. We delivered 21% revenue growth, generated our third consecutive quarter of positive adjusted EBITDA, expanded our international footprint with the launch of Esteem in Europe, and announced two strategic licensing agreements that further strengthen our long-term portfolio."
David Moatazedi, President and Chief Executive Officer
"We posted revenue growth above 20%, delivered our third consecutive quarter of positive adjusted EBITDA and strengthened our confidence and outlook for the remainder of the year. We achieved these results while continuing to invest in customer experience and education, consumer rewards, and the launch of the Esteem portfolio in Europe."
Tatjana Mitchell, Chief Financial Officer
Strategic Positioning
1. Portfolio Growth Bundle Drives Deeper Account Penetration
Evalyst’s portfolio growth bundle, a cross-sell program incentivizing clinics to adopt multiple products, has rapidly shifted customer behavior. In its first six months, 70% of bundle participants purchased Avelis, compared to just 25% among all customers. This initiative is expanding share of wallet and increasing account stickiness, with bundled customers purchasing 2.5 times more volume year-to-date than single-product buyers.
2. Expansion into Skin Quality Vertical with Profilo
The licensing of Profilo, a skin quality injectable, adds a third growth vertical and positions Evalyst as a comprehensive injectable platform. Profilo is a leader in Europe and will be developed for the U.S. market, targeting approval around 2030. This move diversifies the portfolio, taps into emerging demand for skin quality treatments, and is expected to generate over $100 million in peak annual revenue.
3. International Scale and Geographic Diversification
International growth is becoming a significant contributor, with recent launches in Europe and expanded rights in Canada, Australia, and New Zealand. The Esteem collection’s European debut and new distribution agreements broaden Evalyst’s global reach and increase its addressable market by $200 million annually. International business is expected to surpass 10% of total revenue in 2026.
4. Operating Leverage and Financial Flexibility
Evalyst’s commercial infrastructure was built for scale, enabling it to absorb new product launches and geographic expansion without eroding profitability. The company maintains a strong cash position and access to $100 million in additional liquidity, supporting both organic growth and strategic investments. Management’s disciplined approach is evident in OpEx control and capital-efficient licensing deals.
5. Pipeline Cadence and R&D Execution
Three new injectable products are slated for introduction over the next four years, with a pipeline cadence designed to sustain growth and leverage Evalyst’s late-stage development expertise. The company’s R&D bandwidth and regulatory experience underpin confidence in bringing new assets like Sculpt and Elise Lips to market on schedule.
Key Considerations
Evalyst’s Q2 performance validates its transition from a single-product company to a diversified aesthetics platform, with several strategic levers in play:
Key Considerations:
- Cross-Sell Momentum: The rapid uptake of Avelis within bundled accounts demonstrates Evalyst’s ability to drive multi-product adoption and deepen practitioner relationships.
- Market Share Gains: Evalyst is outpacing underlying U.S. and European market growth, with mid-teens share in both toxins and fillers, and strong momentum in key international markets like the UK.
- Emerging Skin Quality Category: Profilo’s entry will create a new revenue stream and further differentiate the portfolio as U.S. consumer awareness grows.
- Operational Discipline: Investments in education, marketing, and international launches have been balanced with margin preservation, supporting a path to long-term profitability.
- GLP-1 Patient Targeting: Evalyst’s co-branded media and product messaging are capitalizing on the influx of weight loss patients, a unique growth vector for the HA gel segment.
Risks
Key risks include regulatory uncertainty, particularly for new product approvals like Profilo, and the timing of international launches that depend on local registration timelines. Tariff exposure remains a watchpoint, especially for HA gels, though current mitigation strategies limit cash impact. Competitive intensity in the aesthetics market, evolving consumer trends, and macroeconomic pressures on discretionary spending could also affect growth and margin trajectory.
Forward Outlook
For Q3 and the remainder of 2026, Evalyst guided to:
- Full-year revenue of $330 million to $337 million, midpoint raised to $333.5 million
- Adjusted gross profit margin of 67.0% to 67.5%
- Non-GAAP operating expenses of $212 million to $216 million
- Low-to-mid single-digit adjusted EBITDA margin for 2026
Long-term, management reaffirmed its 2028 targets of $450 million to $500 million in annual revenue and 13% to 15% adjusted EBITDA margin. Factors supporting the outlook include:
- Sustained market share gains and strong customer adoption of bundled offerings
- Accelerating international contribution and new product launches
Takeaways
Evalyst’s Q2 results signal a durable shift to a multi-vertical, international aesthetics platform with strong operational execution.
- Cross-Sell Drives Share Gains: The portfolio bundle is expanding wallet share and increasing customer loyalty, with bundled accounts delivering outsized growth.
- Pipeline and International Expansion De-Risk Growth: New product launches and expanded geographies diversify revenue streams and create long-term optionality.
- Watch Margin Leverage and Regulatory Milestones: Investors should monitor operating leverage as the portfolio scales, and track development timelines for Profilo and other pipeline assets.
Conclusion
Evalyst’s Q2 marked a strategic inflection, with portfolio breadth, disciplined execution, and international momentum driving both near-term outperformance and long-term growth visibility. The company’s cross-sell engine and pipeline cadence set the stage for continued share gains and expanding profitability.
Industry Read-Through
Evalyst’s results underscore a broader rebound in the injectable aesthetics market, with both neurotoxin and HA gel categories returning to growth after prior declines. The success of cross-sell initiatives and bundled offerings may prompt peers to accelerate portfolio integration and customer engagement strategies. The emergence of the skin quality injectable category, led by Profilo, signals a new growth vector that could reshape competitive dynamics in the U.S. and abroad. Finally, targeted marketing to GLP-1 patients highlights the importance of adapting product messaging to evolving consumer health trends, a tactic likely to gain traction across the industry.